title: The role of Skp2 in extranodal NK/T-cell lymphoma.
abstract: OBJECTIVE
  Expression of Skp2 was related with the prognosis of several tumors. However, there was no intensive study on the relationship between Skp2 and extranodal NK/T cell lymphoma. This study was to explore the role of Skp2 in extranodal NK/T cell lymphoma.
  
  
  METHODS
  The clinicopathological data of 39 patients with extranodal NK/T cell lymphoma were analyzed. The expression of Skp2 was examined by immunohistochemistry on formalin fixed, paraffin embedded tissue sections.
  
  
  RESULTS
  Among the patients with high expression of Skp2, complete remission (CR) rate was only 14.3% (2/14). However, CR rate among the patients with low expression of Skp2 was 68.0% (17/25). Significant difference was shown between these two groups (P < 0.001). In the group of low expression, the median overall survival (OS) was 85.59 months (95% CI: 35.83 135.34 months), the 1 and 2 year OS rates were 81% and 71%, respectively. However, in the group of high expression, the median OS was only 9.73 months (95% CI: 2.05-17.40 months), the 1 and 2 year OS rates were 42% and 14%, respectively. There was statistical difference between these two groups (P < 0.001). Multivariate analysis showed that Skp2 expression (P <0.001), LDH (P = 0.026) and ECOG PS (P = 0.003) were dependent prognostic factors of extranodal NK/T cell lymphoma.
  
  
  CONCLUSIONS
  High expression of Skp2 is an independent unfavorite adverse prognostic factor of extranodal NK/T cell lymphoma.
authors.affiliation: State Key Laboratory of Oncology in South China, Guangzhou, Guangdong 510060, PR China.
authors.forename: Hong-Qiang
authors.initials: HQ
authors.lastname: Guo
authors.forename: Xing-Xiang
authors.initials: XX
authors.lastname: Pu
authors.forename: Cheng-Cheng
authors.initials: CC
authors.lastname: Guo
authors.forename: Hui-Lan
authors.initials: HL
authors.lastname: Rao
authors.forename: Hao-Ran
authors.initials: HR
authors.lastname: Li
authors.forename: Tong-Yu
authors.initials: TY
authors.lastname: Lin
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood; D054391:Lymphoma, Extranodal NK-T-Cell / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D012074:Remission Induction; D044786:S-Phase Kinase-Associated Proteins / Q000378:metabolism*; D015996:Survival Rate; D055815:Young Adult
chemical_list: D044786:S-Phase Kinase-Associated Proteins; D007770:L-Lactate Dehydrogenase